Clinical trial · Observational
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
Change in Neutrophil to Lymphocyte Ratio (NLR) and Survival Among Advanced Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With Immunomodulator: a Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1：ICI treatment with immunomodulator
- description
- Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.
- label
- Cohort 2：ICI treatment without immunomodulator
- description
- Lung cancer patients received immunological checkpoint inhibitors (ICIs).
Primary outcomes (1)
- measure
- Neutrophil to lymphocyte ratio (NLR)
- timeFrame
- Baseline, 4~8 week
Secondary outcomes (1)
- measure
- Overall Survival (OS)
- timeFrame
- 4 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria * Aged 20 years and older. * Patients who have been given a diagnosis of lung cancer. * Previously advanced lung cancer patients first treated with ICIs from Oct 1, 2015 to Oct 31, 2019. Exclusion Criteria * Patients who have no hematological laboratory data available at baseline (within 3 days prior to ICI treatment) and the 6th week (± 2 weeks) after ICI treatment initiation.
References
Publications (0)
Data not yet available